Recon: FDA panel weighs MDMA drug for PTSD; Annexon says GBS drug succeeds in Phase 3 trial
ReconJason Scott
Advisory committeesBiologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States